Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Syridex Bio is a venture capital firm founded in 2022 by Squire Servance, based in Princeton, New Jersey. The firm focuses on building companies that address inequities in health innovation, particularly for underserved communities. Syridex Bio combines venture creation and private equity strategies to develop therapies for diseases disproportionately affecting ethnic minorities, LGBTQ+ communities, and rural populations.
As of now, Syridex Bio has been selected by the New Jersey Economic Development Authority (NJEDA) to invest up to $5 million in early-stage life science companies in New Jersey. This selection underscores the firm's credibility and commitment to enhancing health outcomes through innovative solutions. The firm operates with a dual strategy: venture creation, which involves building companies around acquired pharmaceutical and biotech products, and private equity, which targets undervalued public pharma and biotech companies for take-private transactions.
Syridex Bio invests in life sciences companies that create innovative solutions for diseases affecting underserved populations. Their investment strategy encompasses seed and Series A stages, primarily within the biotech, healthcare, and digital health sectors. The firm emphasizes rigorous due diligence to identify emerging fields of science and medicine, ensuring that health innovations are accessible and equitable.
The firm’s thesis centers on health equity and social impact, focusing on diseases that disproportionately affect ethnic minorities, LGBTQ+ communities, and rural populations. Syridex Bio aims to build agile, well-capitalized companies that can effectively address these challenges. Their approach includes acquiring existing products and assets, allowing them to create sustainable ventures that prioritize health outcomes for underserved communities.
Syridex Bio's portfolio includes two notable companies:
These companies exemplify Syridex Bio's commitment to addressing health inequities through innovative solutions in the life sciences sector.
Squire Servance - Founder & Managing Partner. Squire has a background in life sciences investing and operations, with a focus on building companies that address health inequities.
Veleka Peeples-Dyer - Partner. Veleka brings extensive experience in healthcare investments and strategic development, contributing to the firm's mission of improving health outcomes.
Joshua Adeoye, MD - Principal. Joshua has a medical background and expertise in health innovation, playing a key role in evaluating investment opportunities.
Christopher Whitfield - Advisory Partner. Christopher provides strategic insights and guidance, leveraging his experience in the life sciences sector to support portfolio companies.
To pitch Syridex Bio, founders should send an email to info@syridexbio.com. A well-structured pitch deck is essential, including details about the business model, market opportunity, competitive landscape, and team qualifications. The firm values clarity and thoroughness in presentations.
Response times can vary, but founders should expect to hear back within a few weeks. Warm introductions are beneficial but not mandatory. The firm appreciates direct communication and clear articulation of how the proposed venture aligns with their investment thesis.
In recent developments, Syridex Bio was selected by the New Jersey Economic Development Authority (NJEDA) to invest up to $5 million in early-stage life science companies in New Jersey. This announcement highlights the firm's commitment to supporting local health innovation.
Additionally, Syridex Bio has been featured in various publications, including DiversityQ, NJBIZ, and Innovations of the World, emphasizing their focus on health equity and the impact of their investments.
What are Syridex Bio's investment criteria?
Syridex Bio focuses on life sciences companies that develop solutions for diseases disproportionately affecting underserved populations. They invest in seed and Series A stages, primarily in biotech, healthcare, and digital health sectors.
How can I apply or pitch to Syridex Bio?
Founders can reach out via email at info@syridexbio.com to discuss potential investment opportunities. A detailed pitch deck outlining the business model, market opportunity, and team is recommended.
What makes Syridex Bio different from other venture firms?
Syridex Bio combines venture creation with private equity strategies, focusing on health equity and social impact. They prioritize building companies around acquired assets rather than traditional early-stage investments.
What is Syridex Bio's geographic focus?
The firm primarily invests in North America, with a specific emphasis on early-stage life science companies in New Jersey, as indicated by their partnership with the NJEDA.
What is Syridex Bio's fund size and check size?
The firm has been allocated up to $5 million by the NJEDA for early-stage investments. Check sizes typically align with seed and Series A funding rounds, which can vary based on the specific opportunity.
What kind of post-investment involvement does Syridex Bio have?
Syridex Bio actively supports its portfolio companies through mentorship, operational guidance, and strategic resources, ensuring they are well-positioned to succeed in their respective markets.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.